However, patients with PsA and inflammatory bowel disease (IBD) are an exception, as IL-17 inhibitors in this group are not recommended owing to the lack of demonstrated efficacy and potential exacerbation of IBD manifestations [96]. The gene discussed is IL17A; the disease is inflammatory bowel disease.